Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuchi Gulati

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
International Journal of Cancer|June 14, 2021
Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumorsEmre Yekedüz, Dario Trapani, Wenxin Xu, et al.
BJU International|September 12, 2024
Differences in mutations across tumour sizes in clear-cell renal cell carcinomaSteven M Monda, Benjamin W Carney, Allison M May, et al.
Cancer Medicine|July 11, 2020
COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspectiveMichelle Marcum, Nicky Kurtzweil, Christine Vollmer, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibitionMcKenzie Crist, Benyamin Yaniv, Sarah Palackdharry, et al.
Endocrine-Related Cancer|May 1, 2025
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancerAlyssa Liang, Shuchi Gulati, Quillan Huang, et al.
Cancer|October 19, 2019
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancerShuchi Gulati, Janki Desai, Sarah M Palackdharry, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Lancet Regional Health. Americas|March 9, 2026
Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019Kevin L'Espérance, Katherine Lin, Daphne Lichtensztajn, et al.
Frontiers in Oncology|December 13, 2021
Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck CancerAdam Luginbuhl, Alyssa Calder, David Kutler, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|June 14, 2021
Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumorsEmre Yekedüz, Dario Trapani, Wenxin Xu, et al.
BJU International|September 12, 2024
Differences in mutations across tumour sizes in clear-cell renal cell carcinomaSteven M Monda, Benjamin W Carney, Allison M May, et al.
Cancer Medicine|July 11, 2020
COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspectiveMichelle Marcum, Nicky Kurtzweil, Christine Vollmer, et al.
Journal for Immunotherapy of Cancer|November 3, 2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibitionMcKenzie Crist, Benyamin Yaniv, Sarah Palackdharry, et al.
Endocrine-Related Cancer|May 1, 2025
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancerAlyssa Liang, Shuchi Gulati, Quillan Huang, et al.
Cancer|October 19, 2019
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancerShuchi Gulati, Janki Desai, Sarah M Palackdharry, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Lancet Regional Health. Americas|March 9, 2026
Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019Kevin L'Espérance, Katherine Lin, Daphne Lichtensztajn, et al.
Frontiers in Oncology|December 13, 2021
Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck CancerAdam Luginbuhl, Alyssa Calder, David Kutler, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
Pageof 5